A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study

Serruys, Patrick W; Garg, Scot; Abizaid, Alexandre; Ormiston, John; Windecker, Stephan; Verheye, Stefan; Dubois, Christophe; Stewart, Jim; Hauptmann, Karl E; Schofer, Joachim; Stangl, Karl; Witzenbichler, Bernhard; Wiemer, Marcus; Barbato, Emanuele; de Vries, Ton; den Drijver, Anne-Marie; Otake, Hiromasa; Meredith, Lynn; Toyloy, Sara and Fitzgerald, Peter (2010). A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention, 6(2), pp. 195-205. Toulouse: Europa Digital & Publishing

Full text not available from this repository. (Request a copy)

Novolimus, a macrocyclic lactone with anti-proliferative properties, has a similar efficacy to currently available agents; however it requires a lower dose, and less polymer, and is therefore conceivably safer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

ISSN:

1774-024X

Publisher:

Europa Digital & Publishing

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

17 Mar 2015 19:12

PubMed ID:

20562069

URI:

https://boris.unibe.ch/id/eprint/1632 (FactScience: 203410)

Actions (login required)

Edit item Edit item
Provide Feedback